Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer pati

[News]

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

More... (http://www.news-medical.net/news/20140930/Trastuzumab-offers-better-outcome-than-lapatinib-for-HER2-positive-breast-cancer-patients.aspx)